case_images: PMC11183107_01
case_images: Fi (A-D) The clinical course according to CT scan findings. (A) The baseline CT scan revealed a mass in the basal segment of the lower lobe of the left lung, with no signs of pre-existing interstitial pneumonia before osimertinib therapy. (B) After 6 days of treatment with osimertinib, chest CT showed diffuse ground-glass opacities in both lungs, with the right side being more pronounced and a significant pleural effusion on the left side. (C) Following 7 days of methylprednisolone treatment, a repeat chest CT demonstrated significant resorption of the diffuse interstitial lesion identified in the previous scan, indicating a positive response to therapy. (D) On 1 January 2024, a follow-up chest CT scan displayed new diffuse ground-glass opacities in both lungs, particularly pronounced in the right lung. (E) A thorough timeline of the patient's clinical progression and treatment protocol.
case_images: fphar-15-1410684-g001.jpg
case_images: PMC11183107_01_fphar-15-1410684-g001.jpg
case_images: F1
case_images: A chest computed tomography (CT) scan revealed bronchial stenosis and occlusion in the lingual segment and dorsal segment of the lower lobe of the left lung, accompanied by peripheral flaky hyperdense shadows, diffuse nodular shadows in both lungs and enlarged lymph nodes in the mediastinum and hilar lymph nodes (Figure 1A). A chest CT scan revealed diffuse ground glass shadows in both lungs, with the right side being more prominent and a large pleural effusion on the left side (Figure 1B). A follow-up chest CT scan demonstrated significant absorption of the two diffuse interstitial lung lesions in comparison to the previous scan (Figure 1C). A chest CT scan revealed the presence of new diffuse ground-glass shadows, predominantly in the right lung (see Figure 1D). A detailed timeline of the patient's clinical course and therapy regimen is presented in Figure 1E.